Observational analysis identifies MRI radiomics signatures for recurrence risk in ER+/HER2- breast cancer, suggesting potential clinical utility.
Motivation: The application of 21-gene assays in clinical practice is jeopardized by the cost and availability. Goal(s): To identify MRI subregion radiomics signatures associated with the Oncotype Dx 21-gene recurrence score (RS). Approach: 154 patients were enrolled. Radiomics features were extracted from intratumoral subregions on T2WI and the last phase of post-enhancement (CL) images, which were combined with clininal-imaging features to construct models for distinguishing high (RS ≥ 26) from low (RS < 26) recurrence risk. Results: The model that combined T2 and CL subregional radiomics features with clinical-imaging characteristics had the highest efficacy, with an AUC of 0.81 for the validation cohort. Impact: This study first identified radiomics signatures using intratumoral subregional features to predict RS accurately and cost-effectively in ER+/HER2- breast cancer.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: